- Gastrointestinal Cancer
  - Gastric Cancer
    - Gastric Cancer
      - ▼**10554:** Phase 1 Study of Trastuzumab Deruxtecan (DS-8201a) in Combination with Azenosertib (ZN-c3) in HER2-Expressing/Amplified Cyclin E-Amplified Gastric/Gastroesophageal Junction Cancer and Other Solid Tumors with HER2 Expression
  - Gastroesophageal cancer
    - Gastroesophageal or Colorectal Cancer
      - **10358:** Phase 1/1B Study of DS8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial) (Dose escalation: advanced solid tumors; Dose expansion: Gastroesophageal or Colorectal Cancer)
  - Colorectal cancer
    - Gastroesophageal or Colorectal Cancer
    - Metastatic colorectal cancer
      - **10605:** Phase I Trial of ZEN-3694 in Combination with Cetuximab and Encorafenib in Patients with Refractory BRAF V600E Metastatic Colorectal Cancer
      - ▼**10579:** Phase I Trial of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors
      - ***10655:** Phase I Clinical Trial of CA-4948 in Combination with FOLFOX Plus Bevacizumab as Frontline Treatment in Patients with Metastatic Colorectal Cancer
      - ***10670:** Phase 1 study of 5-fluorouracil in combination with abemaciclib in metastatic, refractory CRC New!
  - Liver and hepatobiliary cancer
    - Cholangiocarcinoma/ gallbladder carcinoma
      - **10276:** A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/ Metastatic Solid Tumors and Hepatobiliary Malignancies (Phase 1: Limited; advanced/metastatic solid tumors; Phase 2: ETCTN-wide; advanced/metastatic hepatobiliary tumors)
      - **10608:** A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma
  - Pancreatic cancer
    - Pancreatic ductal adenocarcinoma
      - **10366:** A Phase 1/2 Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
      - **10522:** A Phase I Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma
    - Unresectable Pancreatic Cancer
      - **10464:** A Phase 1 Study of Olaparib in Combination with Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer
  - Neuroendocrine Tumors
    - Gastroenteropancreatic / Pancreatic Neuroendocrine Tumors
      - **10479:** A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: April 24, 2024